Last reviewed · How we verify
NCT00750217
Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.
Phase 4 trial testing Buprenorphine patch and sublingual tablets in Heroin Addiction in 10 participants. Status unknown.
1 February 2009
Quick facts
| Lead sponsor | Psychiatric University Hospital, Zurich |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 August 2008 |
| Primary completion | 1 February 2009 |
| Estimated completion | 1 May 2009 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Buprenorphine patch and sublingual tablets — full drug profile →
Conditions studied
- Heroin Addiction — all drugs for Heroin Addiction →
Sponsor
Psychiatric University Hospital, Zurich
Who can join
Adults 18 to 60, any sex, with Heroin Addiction. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Short Opiate Withdrawal Scale
Time frame: 14 days
Sponsor's own description
Buprenorphine is an important alternative to methadone in the maintenance treatment of heroin addiction. Transfer from methadone to buprenorphine requires a reduction of daily methadone dosage below 30 mg to avoid withdrawal after the first buprenorphine intake. The study hypothesis states that the transfer from a daily methadone dosage between 60 mg and 100 mg to buprenorphine can be carried out without withdrawal using buprenorphine patches (35 micro grams per hour) within 12 to 48 hours after last methadone intake.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00750217
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Psychiatric University Hospital, Zurich trials
Trials by the same sponsor.
- NCT04100213 — Real-Time Assessment of Stress and Stress Response · NA · withdrawn
- NCT05939765 — Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study. · withdrawn
- NCT04096625 — Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS) · NA · unknown
- NCT05902819 — Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories · NA · completed
- NCT05911529 — Motivational Interviewing for Patients With Acute Psychosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00750217 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psychiatric University Hospital, Zurich
- Last refreshed: 9 September 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00750217.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing